2014 KEY OPINION LEADER PROGRAM
Thought leaders from industry, academia, government and medical research foundations share their insights on the opportunities and challenges that impact the discovery and development of new therapies.
FRESH PERSPECTIVES AND NEW OPPORTUNITIES IN ALZHEIMER’S DISEASE THERAPEUTIC DEVELOPMENT
More than 5 million Americans suffer from Alzheimer’s disease today, and without new drugs to prevent or halt progression that number is expected to increase to 15 million by 2050. Cost of care will increase from $200 billion to a staggering $1.2 trillion a year. Our panelists will touch upon the challenges of developing new therapeutic options for AD, and explore emerging approaches that hold promise in the fight against Alzheimer’s disease. From novel in-silico design and computational approaches to disease progression, to new applications of FDA approved drugs and traditional drug development approaches, the session will explore the latest, and most promising advances in the field of AD research.
- Moderator: Howard Fillit, MD, Founding Executive Director and Chief Science Officer, Alzheimer’s Drug Discovery Foundation
- Michela Gallagher, PhD, Krieger Eisenhower Professor, Psychology & Neuroscience, Johns Hopkins School of Medicine; Founder and Chief Scientific Officer, Agenebio
- Magali Haas, MD, PhD, Founder and Chief Executive Officer, Orion Bionetworks
- Ashish Raj, PhD, Associate Professor of Neuroscience, Brain Mind Research Institute, Weill Cornell Medical College
- Rachel Schindler, MD, Vice President, Clinical Disease Area Expert, Neurosciences & Alzheimer’s disease, Pfizer, Inc.